Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario
- PMID: 11563212
- PMCID: PMC81418
Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario
References
-
- Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30. - PubMed
-
- Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Toronto: Oxford University Press; 1996.
-
- Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993;3:354-61. - PubMed
-
- Torrance GW, Blaker D, Detsky AS, Kennedy W, Schubert F, Menon D, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996;9:535-59. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical